The conversion of pulmonary artery smooth muscle cells to eosinophil-like cells exacerbates the progression of pulmonary arterial hypertension with increased secretion of 12-HETE.
文献摘要
Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary arterial (PA) vascular remodeling, with abnormal phenotypic transformation of pulmonary artery smooth muscle cells (PASMCs) playing a central role. Arachidonic acid (AA) metabolites have been implicated in this process, yet the underlying cellular and molecular mechanisms by which its metabolite 12-hydroxyeicosatetraenoic acid (12-HETE) contributes to PAH remain incompletely understood. Plasma concentrations of 12-HETE were significantly elevated in PAH patients. In SU5416/hypoxia (SuHx)-induced PAH mouse model, the 12/15-lipoxygenase (12/15-LOX) inhibitor ML-351 markedly attenuated disease progression. Single-cell RNA sequencing (scRNA-seq) analysis revealed a unrecognized phenotypic transdifferentiation of a subset of PASMCs into eosinophil-like (Eos-like) cells. Mechanistically, studies utilizing EOS-deficient (ΔdblGATA) mice demonstrated that these newly Eos-like cells, along with native eosinophils (EOS), secrete 12-HETE. In vitro CCK-8 assays confirmed that hypoxia-induced PASMC proliferation was attenuated by the leukotriene B4 receptor 2 (BLT2) antagonist LY255283, confirming that the 12-HETE/BLT2 axis drives PASMC proliferation, thereby creating a positive feedback loop that amplifies vascular remodeling. These findings establish the 12-HETE as a critical mediator of a novel EOS-PASMC signaling axis that drives PA vascular remodeling in PAH. This study highlights a promising new therapeutic strategy for PAH.